TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04729972

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NT-501 CNTF implant
Description: Single implantation of CNTF-secreting NT-501 device into one eye
Study: NCT04285710

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Debridement Surgery and Wound Dressing
Description: All patients enrolled in the study will undergo standard care and treatment for infected diabetic wounds, which includes the weekly surgical removal of infected necrotic tissue from the diabetic wounds. In addition to debridement, both groups will utilize an antimicrobial wound dressing to cover and treat the infected diabetic wound. The subject's wounds will be dressed with Aquacel Ag Advantage Wound Dressings to protect and treat their diabetic wounds. These dressings will be changed twice a week by clinicians.
Study: NCT05813184

Intervention type: DRUG
Intervention: Antibiotics
Description: Any antibiotic therapy administered \> 7 days
Study: NCT05894356

Intervention type: OTHER
Intervention: Study chart review
Description: Evaluation of 4250 sperm DNA fragmentation samples with the goal of defining a cut-off age beyond which SDF levels increase significantly
Study: NCT05822037

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT0594CP
Description: Cell injection
Study: NCT05389397

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Outreach
Description: Mailed letter, secure message or telephone outreach will be used depending on arm enrolled

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Outreach
Description: Mailed letter, secure message or telephone outreach will be used depending on arm enrolled

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Outreach
Description: Mailed letter, secure message or telephone outreach will be used depending on arm enrolled
Study: NCT06354530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib
Description: Drug: Camrelizumab 200mg on Day 1 of each 3-week cycle for 2 cycles during the neoadjuvant period~Drug: Carboplatin Area under the curve of 5 on Day 1 of each 3-week cycle for 2 cycles~Drug: Cisplatin 75 mg/m2 on Day 1 of each 3-week cycle, for 2 cycles~Drug: Paclitaxel 135-175 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Drug: Nab-Paclitaxel 220-260 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Drug: anlotinib 8 mg/day orally (from days 1 to 14 in a 21-day cycle) for 2 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy
Description: Drug: Camrelizumab 200mg on Day 1 of each 3-week cycle for 2 cycles during the neoadjuvant period~Drug: Carboplatin Area under the curve of 5 on Day 1 of each 3-week cycle for 2 cycles~Drug: Cisplatin 75 mg/m2 on Day 1 of each 3-week cycle, for 2 cycles~Drug: Paclitaxel 135-175 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Drug: Nab-Paclitaxel 220-260 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Thoracic radiotherapy RT once daily (from cycle 1 \[C1D1\], 41.4Gy/23Fx, 1.8Gy daily, for 4.6 weeks, 5 days/week)
Study: NCT04809519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative Nursing based Multimodal Interventions for Uncontrolled Hypertensives
Description: In this study, multimodal interventions including yoga, meditation, and breathing techniques, compliance training for hypertension treatment, and home blood pressure measurement training will be applied to the experimental group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ongoing treatment
Description: The ongoing health service of the control group will continue. In addition, the control group will be directed to a specialist doctor and standard brochures prepared by the Ministry of Health for hypertensive individuals will be given.
Study: NCT05680818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encaleret
Description: Administered as film-coated tablet for oral use
Study: NCT05285761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of extended information on the conduct of complementary feeding
Description: Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will receive generic information contained in the health record and in connection with the general development. These 48 messages will be delivered regularly by a smartphone application from the 3rd months until the 36th months of the child.~In addition to the paper brochure and the generic information, parents in the intervention group will also receive the new recommendations relating to CF through an educational device (in the form of a smartphone application). This app will deliver information and very short videos illustrating various aspects of responsive feeding during CF and taking up the themes of the paper brochure. These 106 messages will be delivered regularly from the 3rd months until the 36th months of the child.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provision of current official information on complementary feeding
Description: Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will also receive generic information contained in the health record and in connection with the general development. These 48 messages will be delivered regularly by a smartphone application from the 3rd months until the 36th months of the child.
Study: NCT05680818

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Standard of Care
Description: Calcium supplements and/or active Vitamin D (calcitriol, alfacalcidol, falecalcitriol, etc.)
Study: NCT05900505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Navigator
Description: The social navigator will assess patient/family needs and help them to access community resources (specific to their community) to address these, while promoting their engagement and self-efficacy.
Study: NCT06525688

Intervention type: OTHER
Intervention: Bone, Serum and Plasma sample
Description: Intervention: Bone samples will be collected during surgery from the femoral neck (which is typically removed and discarded in these operations) and fasting morning blood samples.
Study: NCT05447936

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Jarlsberg cheese
Description: Jarlsberg cheese is a regular cheese for free sale in grocery stores. The allotted amount of cheese was taken orally each day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Jarlsberg cheese
Description: Jarlsberg cheese is a regular cheese for free sale in grocery stores. The allotted amount of cheese was taken orally each day
Study: NCT05279183

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Erythritol
Description: Subject specific dose of erythritol dissolved in 300 mL tap water.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: 30 g sucrose dissolved in 300 mL tap water.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sucralose
Description: Subject specific dose of sucralose dissolved in 300 mL tap water.
Study: NCT06497998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical characterization
Description: The oocyte is placed in a culture dish with IVF culture medium. This procedure is similar to that used in the ICSI procedure, except that the injection pipette is replaced by a glass indenter. The indenter (sterile, single-use, blunt-edged glass cylinder, L:16mm, ø:0.85mm, mass:8mg) is completely decoupled from the micromanipulation and microinjection platform and driven by the principle of a magnetic spring with negative stiffness.~The oocyte is immobilized using a restraining pipette to prevent unwanted movement during measurement.~The main objective is to investigate the prognostic value of parameters derived from kinetic measurements of microforces on mature human oocytes in the context of IVF with ICSI.~On each oocyte the mechanical testing is divided in 4 successive loading unloading phase to measure:~* global elasticity of the oocyte.~* global viscosity behaviour of the oocyte.~* local elasticity of the oocyte.~* local viscosity behaviour of the pellucid membrane.
Study: NCT04600726

Intervention type: OTHER
Intervention: no intervention
Description: no interventioni
Study: NCT04734769

Intervention type: OTHER
Intervention: Collect retrospectively clinical data on reproductive outcomes
Description: Collect retrospectively clinical data on reproductive outcomes

Intervention type: OTHER
Intervention: Collect retrospectively clinical data on reproductive outcomes
Description: Collect retrospectively clinical data on reproductive outcomes
Study: NCT06460831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcatheter
Description: The microcatheter group undergoes alcohol ablation using a microcatheter.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: OTW
Description: The OTW group undergoes alcohol ablation using an OTW balloon.
Study: NCT04600726

Intervention type: OTHER
Intervention: no intervention
Description: no interventioni

Intervention type: OTHER
Intervention: no intervention
Description: no interventioni
Study: NCT04989881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: da Vinci Simulator
Description: Single training session

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laparascopic training box
Description: Single training session
Study: NCT06374901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Preoperative treatment with Tislelizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Preoperative treatment with Tislelizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX/XELOX
Description: Preoperative treatment with SOX/XELOX

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOX/XELOX
Description: Preoperative treatment with SOX/XELOX
Study: NCT05597358

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Laser Therapy (HILT)
Description: Nd:Yag 1064 nm pulsed high intensity laser will be applied to the vulvar area.

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Sham High Intensity Laser Therapy
Description: Nd:Yag 1064 pulsed high intensity laser deactivated probe will be applied to the vulvar area.
Study: NCT05933967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib+R-CHOP
Description: Orelabrutinib 150mg qd PO. Rituximab 375 mg/m2 IV on Day 0 of each 21-day cycle. The CHOP include cyclophosphamide, doxorubicin/Epirubicin/liposomal doxorubicin, vincristine/Vindesine, and prednison.
Study: NCT04492241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution
Description: TID for 6 month after enrolment Glass oral bottle, 10 ml/bottle. Study Arm Component: Ginkgo Leaf Extract and Armillariella Mellea Powder, konjac (sweetener), purified water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution
Description: TID for 6 month after enrolment Glass oral bottle, 10 ml/bottle. Placebo Arm Component: Caramel color (food color), konjac (sweetener), sucrose octaacetate (food additive), sodium benzoate (food additive), purified water.
Study: NCT06374901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX/XELOX
Description: Preoperative treatment with SOX/XELOX
Study: NCT04884750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECA-ACE Vaccination Promotion Intervention
Description: A smartphone-based embodied conversational agent that educates users and motivates them to obtain vaccinations for SARS-CoV-2 and Influenza, according to Boston Public Health Commission guidelines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECA-ACE Vaccination Promotion Intervention
Description: A smartphone-based embodied conversational agent that educates users and motivates them to obtain vaccinations for SARS-CoV-2 and Influenza, according to Boston Public Health Commission guidelines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECA-ACE Vaccination Promotion Intervention
Description: A smartphone-based embodied conversational agent that educates users and motivates them to obtain vaccinations for SARS-CoV-2 and Influenza, according to Boston Public Health Commission guidelines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECA-ACE Vaccination Promotion Intervention
Description: A smartphone-based embodied conversational agent that educates users and motivates them to obtain vaccinations for SARS-CoV-2 and Influenza, according to Boston Public Health Commission guidelines.
Study: NCT05662540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography/Magnetic Resonance (PET/MR)
Description: 18F-FDG PET/MR imaging (manufacturer: Siemens, model: Biography mMR). Research devices are marketed products.
Study: NCT05449041

Intervention type: DEVICE
Intervention: Bulbicam
Description: Measurement of eye pressure; Accuracy diagram; Contrast chart; Visual field, Pupil size

Intervention type: DEVICE
Intervention: Bulbicam
Description: Measurement of eye pressure; Accuracy diagram; Contrast chart; Visual field, Pupil size

Intervention type: DEVICE
Intervention: Bulbicam
Description: Measurement of eye pressure; Accuracy diagram; Contrast chart; Visual field, Pupil size

Intervention type: DEVICE
Intervention: Bulbicam
Description: Measurement of eye pressure; Accuracy diagram; Contrast chart; Visual field, Pupil size
Study: NCT04768205

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinesio tape
Description: The Kinesio tex tape is a medical tape that had been certified and patented.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio tape
Description: The Kinesio tex tape is a medical tape that had been certified and patented.
Study: NCT05082519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IDEAL2 Intervention
Description: Intervention of diet and exercise to improve outcomes for ALL patients
Study: NCT05955664

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: MRI indlcuding DTI
Description: A novel technique in MR imaging, which allows tracking of the pelvic floor muscle fibers, Diffusion Tensor Imaging (DTI) will be performed in addition to the standard scanning protocol. We think that MRI with DTI is superior to routine MRI in visualization of LAM.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI indlcuding DTI
Description: A novel technique in MR imaging, which allows tracking of the pelvic floor muscle fibers, Diffusion Tensor Imaging (DTI) will be performed in addition to the standard scanning protocol. We think that MRI with DTI is superior to routine MRI in visualization of LAM.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Pelvic floor ultrasound.
Description: The patient will be scanned in a supine position and the probe is inserted into the vagina in the neutral position to avoid excessive pressure on surrounding structures to avoid distortion of the anatomy. The 3D data automatic acquisition takes approximately 70 seconds.~The analysis of the ultrasound images will be performed on the Trust computers by Radiologists experienced in pelvic floor ultrasound.~Participant will be asked to complete a VAS score for the US.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor ultrasound.
Description: The patient will be scanned in a supine position and the probe is inserted into the vagina in the neutral position to avoid excessive pressure on surrounding structures to avoid distortion of the anatomy. The 3D data automatic acquisition takes approximately 70 seconds.~The analysis of the ultrasound images will be performed on the Trust computers by Radiologists experienced in pelvic floor ultrasound.~Participant will be asked to complete a VAS score for the US.
Study: NCT06374901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOX/XELOX
Description: Preoperative treatment with SOX/XELOX
Study: NCT03517098

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The ERAS group
Description: ERAS pathway for orthopedic surgeons:~1. Shortened preoperative fasting from intake.~2. Preoperative tranexamic acid administration.~3. No indwelling catheters.~4. No tourniquet used for TKA.~5. No drainage tube.~6. Application of the low molecular heparin 6 hours after the operation.~ERAS pathway for anesthesiologist:~1. Intravenous 20 mg of dexamethasone before anesthetic induction.~2. Anesthesia will be induced with small dose of long-acting opioids such as sulfentanil, or without long-acting opioids at all.~3. Laryngeal mask for airway.~4. Anesthesia will be maintained with short-acting anesthetic agents such as desflurane, sevoflurane, or propofol, with continuous remifentanil , and BIS value will be kept between 40 to 60 during procedure.~5. Incision infiltration with 40-50ml of 0.2% ropivacaine, and no patient controlled intravenous analgesia devices will be applied.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: The non-ERAS group
Description: Patients undergoing THA or TKA will receive conventional care according to different participating center, and there's no standard protocol for pre-operative management, anesthetic technique or medication choice, postoperative analgesia or food intake, or catheters indwelling.
Study: NCT05553769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training, detraining, retraining
Description: Participants (healthy untrained men and women, age 18-40) start with a 3-week familiarization and baseline measurement period. After that, they are randomized to two intervention groups, where other group will conduct 10-week RT intervention and a 10-week DT period and again the exact same 10-week RT intervention again whereas the other group start with a 10-week non-training period and then continues with a 20-week RT intervention. RT consists of two training sessions per week of total body workouts. Same measurements are conducted for both groups with the same time intervals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training, detraining, retraining
Description: Participants (healthy untrained men and women, age 18-40) start with a 3-week familiarization and baseline measurement period. After that, they are randomized to two intervention groups, where other group will conduct 10-week RT intervention and a 10-week DT period and again the exact same 10-week RT intervention again whereas the other group start with a 10-week non-training period and then continues with a 20-week RT intervention. RT consists of two training sessions per week of total body workouts. Same measurements are conducted for both groups with the same time intervals.
Study: NCT04234191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: Buprenorphine/naloxone is an opioid agonist treatment for opioid use disorder. It is administered via sublingual tablet form.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine/naloxone
Description: Buprenorphine/naloxone is an opioid agonist treatment for opioid use disorder. It is administered via sublingual tablet form.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Hydromorphone is an opioid used for managing pain, craving, and withdrawal. It is administered orally via tablet or liquid form; or administered intravenously, subcutaneously, or intramuscularly via liquid form.
Study: NCT06259721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD1 antibody, nimotuzumab and capecitabine
Description: Combination phase Anti-PD1 monoclonal antibody: Choose one of the anti-PD-1 monoclonal antibody drugs reimbursed by medical insurance, toripalimab (240mg), camrelizumab (200mg), tislelizumab (200mg) or others; Intravenous infusion, every 3 weeks .~Nimotuzumab:: In the first 6 cycles, 200 mg, intravenous infusion, every 1 week, and 400 mg is administered for the first time.~Capecitabine: 1000 mg/m2, orally twice daily on days 1-14, every 3 weeks~Maintenance phase:~Anti-PD1 monoclonal antibody: anti-PD-1 monoclonal antibody drugs, Intravenous infusion, every 3 weeks.~Nimotuzumab treatment: 400 mg, intravenous infusion, every 3 weeks. Capecitabine: 1000 mg/m2, orally twice daily on days 1-14, every 3 weeks；~The duration of treatment is 1 year or until intolerable toxic reactions occur, or disease progresses, or the patient withdraws consent, or the investigator determines that the patient needs to withdraw from treatment.
Study: NCT05376956

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: Using Muscle Energy Technique in Individuals With Hamstring Shortness

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Proprioception neuromuscular facilitation (PNF)
Description: Using proprioception neuromuscular facilitation (PNF) in Individuals With Hamstring Shortness
Study: NCT06077201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HBCR hands-off
Description: Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance.
Study: NCT06275698

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Manuka honey MGO 1000
Description: Natural Manuka honey, produced in New Zealand. With MGO content ≥ 1000.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar-based syrup, thickened with sodium alginate and flavoured with honey flavouring
Description: Sugar-based syrup, thickened with sodium alginate and flavoured with honey flavouring, 15ml, three times a day, for 14 days.~To be kept on the tongue for at least 10 seconds prior to swallowing.
Study: NCT05199662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous tenecteplase
Description: Intravenous tenecteplase (TNK). Patients will receive intravenous TNK (0.25mg/kg, maximum 25mg, administered as a bolus over 5 seconds).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching IV TNK
Study: NCT05384574

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: daily supplementation of cholecalciferol, 10 000 IU, during 14 days
Study: NCT06077201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HBCR interactive
Description: Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance. Additionally, there are periodic video calls with an exercise physiologist.